



Vascular Therapies

## Vascular Therapies to Participate in the SVB Leerink 9th Annual Global Healthcare Conference

**CRESSKILL, N.J.**, February 11, 2020 – Vascular Therapies, a clinical-stage biopharma company focused on improving vascular access outcomes in patients with kidney disease, today announced that the company will participate in the SVB Leerink 9<sup>th</sup> Annual Global Healthcare Conference, taking place February 25-27, 2020, in New York, NY.

Chief Executive Officer, John McDermott, is scheduled to present on Tuesday, February 25, at 1:30 p.m. ET.

### **About Vascular Therapies**

Vascular Therapies, Inc., is a privately held, biopharma company developing Sirogen, a proprietary sirolimus formulation for local, perivascular drug delivery. The goal of this therapeutic approach is to improve vascular surgery outcomes in patients with kidney and vascular diseases. This investigational therapy is currently being evaluated in a Phase 3 randomized clinical trial, which is being performed under a Special Protocol Assessment (SPA). The drug development program has received Fast Track status from the FDA and sirolimus has Orphan Drug Designation for dialysis vascular access indications in the U.S. and E.U. The FDA has tentatively approved the proprietary tradename Sirogen. Sirogen is an investigational product and has not been determined by the FDA to be safe and effective for any use. For more information, please go to [www.vasculartx.com](http://www.vasculartx.com).

Sirogen is a registered trademark of Vascular Therapies, Inc.

###

**Company Contacts:**

John McDermott  
Chief Executive Officer  
Vascular Therapies, Inc.  
jmcdermott@vasculartx.com  
201-266-8310

Laurence Watts  
Gilmartin Group  
laurence@gilmartinir.com  
619-916-7620